Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen’s $125 Per Share Offer For Onyx Reflects Kyprolis Uncertainty

Aug 26 2013

• By Jessica Merrill

Related Content

Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace

Jun 17 2013

How <em>Kyprolis </em>Overcame Serious Safety Fears To Reach Myeloma Market With Clean Label

Jul 30 2012

Onyx’s Transformative Year: From Productive Partner To Big Cap Contender?

Mar 19 2013

Onyx Sees Blockbuster In Oncology Drug Carflizomib, Buys Proteolix To Get It

Oct 12 2009

Onyx Starts Acquisition Process; Price And Competition To Come Into Play

Jul 01 2013

Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back

May 13 2013

Related Companies

Amgen, Inc.

Onyx Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Pharmasset, Inc.

Amgen, Inc.

Bayer AG

Pfizer Inc.

Micromet, Inc.

Cetus Oncology Corp.

Proteolix

Additional Topics

Deals BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window